Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about JNJ, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Teclistamab FDA approved Oct 2022 · Tecvayli |
Multiple Myeloma | Phase 4 · NCT07030517 | Active not recruiting |
| Talquetamab FDA approved Aug 2023 · Talvey |
Multiple Myeloma (MM) | Phase 3 · NCT07649525 | Recruiting |
| Daratumumab FDA approved Nov 2015 · Darzalex |
Multiple Myeloma (MM) | Phase 3 · NCT07649525 | Recruiting |
| Hafnium Oxide-containing Nanoparticles NBTXR3 | Carcinoma, Squamous Cell | Phase 3 · NCT04892173 | Recruiting |
| Infliximab | Cytokine Release Syndrome | Phase 2 · NCT07657312 | Recruiting |
| JNJ-1761981 | Neoplasms | Phase 1 · NCT07525141 | Recruiting |
| Adenosine A2A Receptor Antagonist JNJ-86974680 | Carcinoma, Non-small-Cell Lung | Phase 1 · NCT06116786 | Active not recruiting |
| Oncolytic HSV-1 JNJ-87704916 | Neoplasms | Phase 1 · NCT06311578 | Recruiting |
| Mezigdomide | Multiple Myeloma | Phase 1 · NCT07105059 | Recruiting |
| Cetrelimab | Neoplasms | Phase 1 · NCT07525141 | Recruiting |
| Pasritamig | Prostate Cancer | Phase 1 · NCT07860255 | Not yet recruiting |
Also used in these trials (approved or third-party drugs, not JNJ's own candidates): Acetaminophen, Naproxen Sodium 220Mg, Lenalidomide, Dexamethasone, Cetuximab, Durvalumab, Cisplatin, Paclitaxel, Carboplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
JNJ holds $20.4B in cash and short-term investments (as of Sep 27, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JNJ files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 209,718,001 | 8.71% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 180,631,228 | 7.50% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 133,971,339 | 5.57% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 65,651,392 | 2.73% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 65,497,363 | 2.72% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 61,752,701 | 2.57% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 44,682,305 | 1.86% | 2026-09-30 |
| State Farm Mutual Automobile Insurance C | Institution (13F) | 31,590,952 | 1.31% | 2026-09-30 |
| Northern Trust Corporation | Institution (13F) | 28,197,333 | 1.17% | 2026-09-30 |
| Joaquin Duato CEO and Chairman of the Board, Director |
Insider | 307,837 | 0.01% | 2026-08-13 |
| Jennifer L Taubert EVP, WWC. Innovative Medicine · +87,521 options |
Insider | 194,451 | 0.01% | 2026-08-17 |
| Kathryn E Wengel EVP, Chief TO and Risk Officer · +51,127 options |
Insider | 114,659 | 0.00% | 2026-06-11 |
Share count 2,407,310,266 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-12 filed 2026-11-13 |
Forminard Elizabeth |
Option exercise (M) | 13,072 | $151.41 | 30,066 |
| 2026-11-12 filed 2026-11-13 |
Forminard Elizabeth |
Sale (S) | 13,072 | $284.39 | 16,994 |
| 2026-11-12 filed 2026-11-13 |
Forminard Elizabeth |
Option exercise (M) | 13,072 | – | – |
| 2026-09-08 filed 2026-09-10 |
Pinto Daniel E |
Option award (A) | 113 | $276.31 | – |
| 2026-09-08 filed 2026-09-10 |
Woods Eugene A. |
Option award (A) | 136 | $276.31 | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JNJ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →